RVMD slides after Needham target cut tied to raised 2026 cost guidance
Needham cut its price target on Revolution Medicines to $183, citing higher 2026 costs after updated equity compensation and raised operating-expense guidance. The move follows the company’s Q1 2026 results and earnings call, which highlighted increased stock-based compensation and a larger net loss.
1. What changed today
On May 7, 2026 (U.S. market day), a new analyst update lowered Revolution Medicines’ price target, pointing to higher costs after changes to the company’s equity compensation program and higher 2026 expense expectations. This is a same-day, specific catalyst that can plausibly pressure shares even without new clinical or regulatory negative news.
2. The specific cost items being flagged
The analyst note ties the change to increased stock-based compensation and higher full-year 2026 cost guidance, including higher GAAP operating expense expectations. In parallel, the company’s Q1 2026 discussion emphasized elevated spending as it accelerates clinical investment, which can amplify sensitivity to any guidance increases.
3. Context (not the catalyst)
Recent RVMD attention has centered on daraxonrasib clinical momentum and other pipeline updates, but those items were reported earlier and are not the same-day driver for May 7. Today’s headline focus is cost/guidance and valuation implications rather than a new FDA action, trial failure, or M&A event.